InsiderDirector

James E Flynn Insider Trading Activity

Every SEC Form 4 transaction reported by James E Flynn, sourced directly from SEC EDGAR and updated as new filings are accepted.

By · SEC Form 4 & insider trading data analysts
Last updated:

Quick Answer

Is James E Flynn buying or selling?

James E Flynn reported 35 open-market buys ($469.4M) and 29 sells ($349.7M) across 64 Form 4 filings at 34 companies — a net buying position of $119.7M.

Source: SEC EDGAR Form 4

Key Statistics (as of Mar 3, 2026)

Total Form 4 filings
64
SEC EDGAR
Companies
34
Buys (35)
$469.4M
Sells (29)
$349.7M

Insider sentiment

Net buying

Net insider flow of $119.7M in net buying, filed between Feb 23, 2018 – Mar 3, 2026.

Companies James E Flynn files for

#CompanyForm 4 filings
1ONCROncorus, Inc.6
2QTTBHomology Medicines, Inc.6
3LRMRLarimar Therapeutics, Inc.5
4XERSXERIS PHARMACEUTICALS INC5
5ACRSAclaris Therapeutics, Inc.4
6MIRMMirum Pharmaceuticals, Inc.4
7NUVLNuvalent, Inc.3
8AFIBAcutus Medical, Inc.2
9AHCOAdaptHealth Corp.2
10GYRECATALYST BIOSCIENCES, INC.2

Recent James E Flynn transactions

DateTickerRoleTypeSharesValue
Mar 3, 2026LRMRDirector, 10% OwnerPurchase5.0M$25.0M
Nov 25, 2025NUVLDirector, 10% OwnerSale742.6K$70.9M
Aug 4, 2025LRMRDirector, 10% OwnerPurchase9.4M$30.0M
Jul 1, 2025SPRY10% OwnerSale740.1K$13.7M
Nov 14, 2024SPRY10% OwnerSale563.3K$10.1M
Oct 24, 2024NUVLDirector, 10% OwnerSale2.0M$195.5M
Sep 17, 2024BCAXOther, 10% OwnerPurchase70.0K$1.3M
Mar 12, 2024AHCOOther, 10% OwnerSale350.0K$3.8M
Feb 16, 2024LRMRDirector, 10% OwnerPurchase4.3M$37.5M
Dec 31, 2022ONCROther, 10% OwnerSale336.2K$88.3K
Dec 27, 2022ONCROther, 10% OwnerSale73.4K$19.9K
Dec 22, 2022ONCROther, 10% OwnerSale128.3K$37.6K
Dec 15, 2022ONCROther, 10% OwnerSale13.8K$5.3K
Nov 7, 2022NUVLDirector, 10% OwnerPurchase650.0K$21.8M
Sep 21, 2022LRMRDirector, 10% OwnerPurchase11.1M$35.0M
Jun 8, 2022MIRMOther, 10% OwnerSale38.5K$962.3K
May 10, 2022PEPGOther, 10% OwnerPurchase416.7K$5.0M
Oct 28, 2021XLOOther, 10% OwnerPurchase775.0K$12.4M
Jul 21, 2021AFIBDirector, 10% OwnerPurchase1.1M$15.0M
Jul 13, 2021MIRMOther, 10% OwnerSale99.3K$1.6M
Jul 7, 2021MIRMOther, 10% OwnerSale66.7K$1.1M
Jul 2, 2021LRMRDirector, 10% OwnerPurchase685.7K$6.0M
Jun 3, 2021OMICOther, 10% OwnerPurchase1.5M$33.0M
May 4, 2021HOWLOther, 10% OwnerPurchase800.0K$12.8M
Mar 30, 2021EWTXOther, 10% OwnerPurchase625.0K$10.0M

Showing the 25 most recent filings of 64. Screen every filing.

James E Flynn insider trading FAQ

Is James E Flynn buying or selling?

Across 64 SEC Form 4 filings, James E Flynn reported 35 open-market purchases totaling $469.4M and 29 sales totaling $349.7M — a net buying position of $119.7M.

Which companies does James E Flynn file Form 4s for?

James E Flynn has reported insider transactions at 34 companies, most often Oncorus, Inc. (ONCR), Homology Medicines, Inc. (QTTB), Larimar Therapeutics, Inc. (LRMR), XERIS PHARMACEUTICALS INC (XERS), Aclaris Therapeutics, Inc. (ACRS).

How far back does James E Flynn's filing history go?

Trabud holds James E Flynn's SEC Form 4 filings from Feb 23, 2018 – Mar 3, 2026, sourced directly from SEC EDGAR.

Where does Trabud get James E Flynn's insider trading data?

Directly from SEC EDGAR Form 4 filings. Every transaction on this page is a real filing accepted by the SEC, updated as new filings arrive.

Related Content

Learn

What is SEC Form 4?

The filing behind every transaction here

Guide

How to Track Insider Trading

A practical workflow for following Form 4 activity

Use Case

Insider Buying Signals

How investors read insider purchases

Track James E Flynn and every other insider

Screen all SEC Form 4 filings by insider, company, transaction value, and role — or ask Trabud's AI agent in plain English.

Open the screener